10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _______________________

Commission file number: 001-37544

ARMATA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Washington	91-1549568
(State or other jurisdiction of	(I.R.S. Employer Identification Number)
incorporation or organization)
5005 McConnell Avenue
Los Angeles, CA	90066
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (310) 665-2928

4503 Glencoe Avenue, Marina Gel Ray, CA

(Former name, former address, and former fiscal year, if changed since last year)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	ARMP	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes   ☒      No     ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes    ☒     No     ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company as defined in Rule 12b-2 of the Exchange Act. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   ☐	Accelerated filer   ☐
Non-accelerated filer     ☒	Smaller reporting company   ☒
	Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐     No ☒

The number of shares of the registrant’s Common Stock, par value $0.01 per share, outstanding as of August 4, 2023 was 36,127,306.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	6
	Condensed Consolidated Balance Sheets	6
	Condensed Consolidated Statements of Operations	7
	Condensed Consolidated Statements of Shareholders’ Equity	8
	Condensed Consolidated Statements of Cash Flows	10
	Notes to Condensed Consolidated Financial Statements	11
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31
PART II. OTHER INFORMATION		32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	33
SIGNATURES		35

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Quarterly Report”) and certain information incorporated herein by reference contain forward-looking statements, which are provided under the “safe harbor” protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to our future financial performance and involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance, or events to be materially different from any future results, performance, or events expressed or implied by the forward-looking statements. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding:

● our estimates regarding anticipated operating losses, capital requirements and needs for additional funds;

● our ability to raise additional capital when needed and to continue as a going concern;

● our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials;

● our clinical development plans, including planned clinical trials;

● our research and development plans, including our clinical development plans;

● our ability to select combinations of phages to formulate our product candidates;

● our development of bacteriophage-based therapies;

● the potential use of bacteriophages to treat bacterial infections;

● the potential future of antibiotic resistance;

● our ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivity to antibiotics;

● our planned development strategy, presenting data to regulatory agencies and defining planned clinical studies;

● the expected timing of additional clinical trials, including Phase 1b/Phase 2 or registrational clinical trials;

● our ability to manufacture and secure sufficient quantities of our product candidates for clinical trials;

● the drug product candidates to be supplied by us for clinical trials;

● the potential for bacteriophage technology being uniquely positioned to address the global threat of antibiotic resistance;

● the safety and efficacy of our product candidates;

● our anticipated regulatory pathways for our product candidates;

● the activities to be performed by specific parties in connection with clinical trials;

● our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all;

● our pursuit of additional indications;

● the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration (the “FDA”) and other regulatory agencies;

● our ability to leverage the experience of our management team and to attract and retain management and other key personnel;

● the capacities and performance of our suppliers, manufacturers, contract research organizations (“CROs”) and other third parties over whom we have limited control;

● our ability to staff and maintain our Marina del Rey production facility under fully compliant current Good Manufacturing Practices (“cGMP”);

● the actions of our competitors and success of competing drugs or other therapies that are or may become available;

● our expectations with respect to future growth and investments in our infrastructure, and our ability to effectively manage any such growth;

● the size and potential growth of the markets for any of our product candidates, and our ability to capture share in or impact the size of those markets;

● the benefits of our product candidates;

● potential market growth and market and industry trends;

● maintaining collaborations with third parties including our partnerships with the Cystic Fibrosis Foundation (“CFF”), and the U.S. Department of Defense (the “DoD”);

● potential future collaborations with third parties and the potential markets and market opportunities for product candidates;

● our ability to achieve our vision, including improvements through engineering and success of clinical trials;

● our ability to meet anticipated milestones in the development and testing of the relevant product;

● our ability to be a leader in the development of phage-based therapeutics;

● the expected use of proceeds from the $16.3 million DoD grant;

● the effects of government regulation and regulatory developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements;

● the accuracy of our estimates regarding future expenses, revenues, capital requirements and need for additional financing;

● our expectations regarding future planned expenditures;

● our ability to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act;

● our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of any of our products and product candidates;

● our ability to protect our intellectual property, including pending and issued patents;

● our ability to operate our business without infringing the intellectual property rights of others;

● our ability to advance our clinical development programs;

● the effects of the ongoing conflict between the Ukraine and Russia and the recent and potential future bank failures or other geopolitical events; and

● statements of belief and any statement of assumptions underlying any of the foregoing.

In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of those terms, and similar expressions. These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Quarterly Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section hereof entitled “Risk Factors” and in our Annual Report on Form 10-K for the year ended December 31, 2022. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain. Given these uncertainties, you should not place undue reliance on any of the forward-looking statements included in this Quarterly Report. In addition, this Quarterly Report also contains estimates, projections, and other information concerning our industry, our business, and the markets for our product candidates, as well as data regarding market research, estimates, and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise.

This Quarterly Report includes trademarks and registered trademarks of Armata Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Quarterly Report may be trademarks or registered trademarks of their respective owners.

As used in this Quarterly Report, unless the context requires otherwise, the “Company,” “we,” “us,” and “our” refer to Armata Pharmaceuticals, Inc. and its wholly owned subsidiaries.

PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

	June 30, 2023		December 31, 2022
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	12,456,000	$	14,852,000
Prepaid expenses		5,745,000		3,664,000
Other receivables		8,633,000		8,531,000
Total current assets		26,834,000		27,047,000
Restricted cash		5,720,000		5,960,000
Property and equipment, net		8,807,000		3,617,000
Operating lease right-of-use asset		43,652,000		43,035,000
In-process research and development		10,256,000		10,256,000
Goodwill		3,490,000		3,490,000
Other assets		2,453,000		2,429,000
Total assets	$	101,212,000	$	95,834,000
Liabilities and shareholders’ equity
Current liabilities
Accounts payable and accrued liabilities	$	9,584,000	$	6,034,000
Accrued compensation		1,098,000		1,828,000
Current portion of operating lease liabilities		14,528,000		17,011,000
Convertible debt		26,352,000		—
Total current liabilities		51,562,000		24,873,000
Operating lease liabilities, net of current portion		27,430,000		31,804,000
Deferred tax liability		3,077,000		3,077,000
Total liabilities		82,069,000		59,754,000
Shareholders’ equity
Common stock, $0.01 par value; 217,000,000 shares authorized; 36,127,306 and 36,144,706 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		361,000		361,000
Additional paid-in capital		276,593,000		275,493,000
Accumulated deficit		(257,811,000)		(239,774,000)
Total shareholders’ equity		19,143,000		36,080,000
Total liabilities and shareholders’ equity	$	101,212,000	$	95,834,000

See accompanying notes to condensed consolidated financial statements.

6

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Grant revenue	$	980,000	$	1,883,000	$	1,776,000	$	3,119,000
Operating expenses
Research and development		8,259,000		9,020,000		17,863,000		17,048,000
General and administrative		2,350,000		2,083,000		4,888,000		4,066,000
Total operating expenses		10,609,000		11,103,000		22,751,000		21,114,000
Loss from operations		(9,629,000)		(9,220,000)		(20,975,000)		(17,995,000)
Other income (expense)
Interest income		46,000		5,000		64,000		6,000
Change in fair value of convertible debt		6,036,000		—		2,874,000		—
Total other income (expense), net		6,082,000		5,000		2,938,000		6,000
Net loss	$	(3,547,000)	$	(9,215,000)	$	(18,037,000)	$	(17,989,000)
Per share information:
Net loss per share, basic	$	(0.10)	$	(0.26)	$	(0.50)	$	(0.55)
Weighted average shares outstanding, basic		36,068,130		35,999,642		36,056,649		32,517,416
Net loss per share, diluted	$	(0.17)	$	(0.26)	$	(0.50)	$	(0.55)
Weighted average shares outstanding, diluted		56,544,698		35,999,642		36,056,649		32,517,416

See accompanying notes to condensed consolidated financial statements.

7

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Shareholders’ Equity

Three and Six Months Ended June 30, 2023 and 2022

(unaudited)

	Shareholders’ Equity
	Common Stock
				Additional				Total
				Paid-in		Accumulated		shareholders’
	Shares	Amount		Capital		Deficit		Equity
Balances, March 31, 2022	36,112,053	$	361,000	$	272,809,000	$	(211,631,000)	$	61,539,000
Issuance cost in connection with sale of common stock	—		—		(32,000)		—		(32,000)
Forfeiture of restricted stock awards	(123)		—		—		—		—
Exercise of stock options	21,775		—		71,000		—		71,000
Return of restricted stock awards for tax withholdings	(5,511)		—		(21,000)		—		(21,000)
Share-based compensation	—		—		949,000		—		949,000
Net loss	—		—		—		(9,215,000)		(9,215,000)
Balances, June 30, 2022	36,128,194	$	361,000	$	273,776,000	$	(220,846,000)	$	53,291,000
	Shareholders’ Equity
	Common Stock
				Additional				Total
				Paid-in		Accumulated		shareholders’
	Shares	Amount		Capital		Deficit		Equity
Balances, March 31, 2023	36,144,706	$	361,000	$	276,350,000	$	(254,264,000)	$	22,447,000
Forfeiture of restricted stock awards	(3,699)		—		—		—		—
Return of restricted stock awards for tax withholdings	(13,701)		—		(18,000)		—		(18,000)
Share-based compensation	—		—		261,000		—		261,000
Net loss	—		—		—		(3,547,000)		(3,547,000)
Balances, June 30, 2023	36,127,306	$	361,000	$	276,593,000	$	(257,811,000)	$	19,143,000

8

	Shareholders’ Equity
	Common Stock
				Additional				Total
				Paid-in		Accumulated		Shareholders’
	Shares	Amount		Capital		Deficit		Equity
Balances, December 31, 2021	27,112,299		271,000	$	227,983,000	$	(202,857,000)	$	25,397,000
Sale of common stock, net of issuance costs	9,000,000		90,000		44,301,000		—		44,391,000
Return of restricted stock awards for tax withholdings	(5,511)		—		(21,000)		—		(21,000)
Forfeiture of restricted stock awards	(369)		—		—		—		—
Exercise of stock options	21,775		—		71,000		—		71,000
Share-based compensation	—		—		1,442,000		—		1,442,000
Net loss	—		—		—		(17,989,000)		(17,989,000)
Balances, June 30, 2022	36,128,194	$	361,000	$	273,776,000	$	(220,846,000)	$	53,291,000
	Shareholders’ Equity
	Common Stock
				Additional				Total
				Paid-in		Accumulated		Shareholders’
	Shares	Amount		Capital		Deficit		Equity
Balances, December 31, 2022	36,144,706	$	361,000	$	275,493,000	$	(239,774,000)	$	36,080,000
Return of restricted stock awards for tax withholdings	(3,699)		—		—		—		—
Forfeiture of restricted stock awards	(13,701)		—		(18,000)		—		(18,000)
Share-based compensation	—		—		1,118,000		—		1,118,000
Net loss	—		—		—		(18,037,000)		(18,037,000)
Balances, June 30, 2023	36,127,306	$	361,000	$	276,593,000	$	(257,811,000)	$	19,143,000

See accompanying notes to condensed consolidated financial statements.

9

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Six Months Ended June 30,
	2023		2022
Operating activities:
Net loss	$	(18,037,000)	$	(17,989,000)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		458,000		421,000
Share-based compensation		1,118,000		1,442,000
Change in fair value of convertible debt		(2,874,000)		—
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		116,000		1,622,000
Accrued compensation		(730,000)		621,000
Operating lease right-of-use asset and liability, net		(7,474,000)		1,781,000
Prepaid expenses and other current assets		(2,207,000)		439,000
Net cash used in operating activities		(29,630,000)		(11,663,000)
Investing activities:
Purchases of property and equipment		(2,232,000)		(1,372,000)
Net cash used in investing activities		(2,232,000)		(1,372,000)
Financing activities:
Proceeds from issuance of convertible debt, net of issuance costs		29,226,000		—
Proceeds from sale of common stock, net of offering costs		—		44,414,000
Proceeds from exercise of warrants and stock options		—		71,000
Net cash provided by financing activities		29,226,000		44,485,000
Net increase in cash, cash equivalents and restricted cash		(2,636,000)		31,450,000
Cash, cash equivalents and restricted cash, beginning of period		20,812,000		11,488,000
Cash, cash equivalents and restricted cash, end of period	$	18,176,000	$	42,938,000
Supplemental disclosure of cash flow information:
Unpaid offering costs	$	—	$	23,000
Property and equipment included in accounts payable	$	3,416,000	$	85,000

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows:

	Six Months Ended June 30,
	2023		2022
Cash and cash equivalents	$	12,456,000	$	36,978,000
Restricted cash		5,720,000		5,960,000
Cash, cash equivalents and restricted cash	$	18,176,000	$	42,938,000

See accompanying notes to condensed consolidated financial statements.

10

Armata Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization and Description of the Business

Armata Pharmaceuticals, Inc. (“Armata”), and together with its subsidiaries, is referred to herein as, the “Company”, is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata’s common stock is traded on the NYSE American exchange under the ticker symbol “ARMP”.

2. Liquidity

The Company has prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.

2023 Credit Agreement

On July 10, 2023, the Company entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder of the Company on July 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025. Repayment of the Loan is guaranteed by the Company’s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company’s operating budget.

2023 Convertible Credit Agreement

On January 10, 2023, the Company entered into, as borrower, a secured convertible credit and security agreement (the “Convertible Credit Agreement”) with Innoviva. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Convertible Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024. Concurrently with the execution of the Credit Agreement, the Company entered into an amendment to that certain secured convertible credit and security agreement (the “First Amendment to Convertible Credit Agreement”). Pursuant to the First Amendment to Convertible Credit Agreement, the parties agreed to, among other things, extend the maturity date from January 10, 2024 to January 10, 2025.

Repayment of the Convertible Loan is guaranteed by the Company’s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

11

 The Convertible Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Convertible Loan shall be converted into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event). The Convertible Credit Agreement also required the Company to file a registration statement (the “Registration Statement”) for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender’s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).

2022 Equity Financing

On February 9, 2022, the Company entered into a securities purchase agreement (“February 2022 Securities Purchase Agreement”) to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase 9,000,000 newly issued shares of the Company’s Common Stock, at a price of $5.00 per share, and warrants to purchase up to 4,500,000 additional shares of Common Stock, with an exercise price of $5.00 per share. The stock purchases closed in two tranches. On February 9, 2022, Innoviva purchased 3,614,792 shares of common stock and warrants to purchase 1,807,396 shares of Common Stock for an aggregate purchase price of approximately $18.1 million. At the closing of the second tranche, following the Company’s shareholders voting in favor of the transaction on March 30, 2022, Innoviva purchased 5,385,208 shares of Common Stock and warrants to purchase 2,692,604 shares of Common Stock for an aggregate purchase price of $26.9 million on March 31, 2022.

As of June 30, 2023, the Company had cash and cash equivalents of $12.5 million. The Company’s current cash resources, along with the funds received in the Loan financing closed in July 2023, that management believes will be sufficient to fund the Company’s planned operations into the first quarter of 2024. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital.

Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing shareholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing shareholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected.

3. Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed

12

consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2022 included in the Company’s Form 10-K, filed with the SEC on March 16, 2023. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company’s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.

In-Process Research and Development (“IPR&D”)

IPR&D assets are intangible assets with indefinite lives and are not subject to amortization. The Company’s IPR&D assets represent capitalized incomplete research projects acquired by the Company, which is related to the development of natural phage combinations for the treatment of Staphylococcus aureus infections (“S. aureus”), examples of which comprise AP-SA01 and AP-SA02. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.

Goodwill

Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company’s consolidated statements of operations.

Basic and Diluted Net Loss per Share

Net earnings or loss per share (“EPS”) is calculated in accordance with the applicable accounting guidance provided in ASC 260, Earnings per Share. The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common shareholders. The two-class method is an earnings allocation

13

formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.

Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.  Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method.

The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common shareholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

Grants and Awards

In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a “customer”, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (“ASC 808”). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.

Armata also considers the guidance in ASC Topic 730, Research and Development (“ASC 730”), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability. If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.

Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.

Leases

The Company determines if an arrangement contains a lease at inception. The Company currently only has operating leases. The Company recognizes a right-of-use operating lease asset and associated short and long-term operating lease liability on its condensed consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liabilities represent the Company’s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term. The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised.

14

As the Company’s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available on the date of adoption of Topic 842, Leases, as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.

Research and Development Expenses

Research and development (“R&D”) costs consist primarily of direct and allocated salaries, incentive compensation, share-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.

Reclassifications

Certain prior year amounts, including tenant improvement receivable and awards receivable, have been reclassified to conform to the current year presentation. Refer to Note 6 Other Receivables table for details.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023 which did not have an impact on its consolidated financial statements or related disclosures.

In August 2020, the FASB issued ​ASU 2020-06​, ​Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)​ (“ASU 2020-06”). ​ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company’s consolidated financial statements.

4. Fair Value Measurements

The Company's Convertible Loan (Note 7) is measured at fair value, which is revalued at each measurement period.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:

15

●Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

●Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

●Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company estimates the fair value of its Convertible Loan (Note 7) using a weighted probability of various scenario of the Convertible Loan during its term, utilizing significant assumptions and estimates such as volatility and risk-free interest rates, which are level 3 fair value inputs unobservable from active markets.

The following table presents the Company’s fair value measurements using level 3 inputs during the three and six months ended June 30, 2023.

	Fair Value
Balance at December 31, 2022	$	—
Net issuance of the Convertible Loan		29,226,000
Change in fair value		3,162,000
Balance at March 31, 2023	$	32,388,000
Change in fair value		(6,036,000)
Balance at June 30, 2023	$	26,352,000

5. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated:

	Three Months Ended		Six Months Ended
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Basic and diluted net loss per common share calculation:
Net loss attributable to common shareholders - basic	($ 3,547,000)	($ 9,215,000)	($ 18,037,000)	($ 17,989,000)
Change in fair value of convertible debt	6,036,000	—	2,874,000	—
Net loss attributable to common shareholders - diluted	($ 9,583,000)	($ 9,215,000)	($ 20,911,000)	($ 17,989,000)
Weighted average common shares outstanding - basic	36,068,130	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - basic	($ 0.10)	($ 0.26)	($ 0.50)	($ 0.55)
Weighted average common shares outstanding - diluted	56,544,698	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - diluted	($ 0.17)	($ 0.26)	($ 0.50)	($ 0.55)

16

The following outstanding securities as of June 30, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:

	June 30, 2023	June 30, 2022
Options	3,201,929	3,380,678
Unvested restricted stock units	30,000	30,000
Restricted stock awards	41,066	99,666
Warrants	20,549,338	20,549,338
Total	23,822,333	24,059,682

6. Balance Sheet Details

Property and Equipment

Property and equipment as of June 30, 2023 and December 31, 2022 consisted of the following:

	June 30, 2023		December 31, 2022
Laboratory and manufacturing equipment	$	15,655,000	$	10,007,000
Furniture and fixtures		817,000		817,000
Office and computer equipment		449,000		449,000
Leasehold improvements		3,447,000		3,447,000
Total		20,368,000		14,720,000
Less: accumulated depreciation		(11,561,000)		(11,103,000)
Property and equipment, net	$	8,807,000	$	3,617,000

Depreciation expense totaled $0.2 million for each of the three months ended June 30, 2023 and 2022, and $0.5 million and $0.4 million for the six months ended June 30, 2023 and 2022, respectively.

Other Receivables

Other receivables as of June 30, 2023 and December 31, 2022 consisted of the following:

	June 30, 2023		December 31, 2022
Tenant improvement receivable	$	7,375,000	$	6,595,000
Awards receivable		1,258,000		1,936,000
	$	8,633,000	$	8,531,000

7. Convertible Debt

As described in Note 2, on January 10, 2023, the Company received a Convertible Loan of $30 million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears an interest rate of 8.0% per annum. The Convertible Loan had a maturity date of January 10, 2024, which was amended to January 10, 2025 in connection with the First Amendment to Convertible Credit Agreement entered into between the Company and Innoviva on July 10, 2023. Repayment of the Convertible Loan is guaranteed by the Company’s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

 The Convertible Credit Agreement provides that if a Qualified Financing occurs, which is defined in the Convertible Credit Agreement as a financing from new investors of at least $30 million, the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company’s common stock, at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by

17

investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file the Registration Statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender’s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).

The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, Distinguish Liabilities from Equity, due to the fact that the Convertible Loan will predominately be settled with the Company’s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its balance sheet, with changes in fair value recorded as other income (expenses) in the statement of operations during each reporting period.

8. Shareholders’ Equity

Private Investment

February 2022 Private Placement

On February 9, 2022, the Company entered into the February 2022 Securities Purchase Agreement to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase 9,000,000 newly issued shares of the Company’s Common Stock, at a price of $5.00 per share, and warrants to purchase up to 4,500,000 additional shares of Common Stock, with an exercise price of $5.00 per share. The stock purchases occurred in two tranches. On February 9, 2022, Innoviva purchased 3,614,792 shares of Common Stock and warrants to purchase 1,807,396 shares of Common Stock for an aggregate purchase price of approximately $18.1 million. On March 31, 2022, upon the Company’s shareholders voting in favor of the transaction, Innoviva purchased 5,385,208 shares of Common Stock and warrants to purchase 2,692,604 shares of Common Stock for an aggregate purchase price of $26.9 million.

Warrants issued to Innoviva expire five years from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity.

Warrants

On June 30, 2023, outstanding warrants to purchase shares of Common Stock are as follows:

Shares Underlying Outstanding Warrants	Exercise Price		Expiration Date
1,183,491	$	5.60	October 16, 2023
993,139	$	2.87	February 11, 2025
7,717,661	$	2.87	March 27, 2025
1,867,912	$	3.25	January 26, 2026
4,285,935	$	3.25	March 16, 2026
1,807,396	$	5.00	February 8, 2027
2,692,604	$	5.00	March 30, 2027
1,200	$	1,680.00	None
20,549,338

18

9. Equity Incentive Plans

Stock Award Plans

The Company maintains a 2016 Equity Incentive Plan (the “2016 Plan”), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable over a four-year period following the date of grant. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually beginning January 1, 2017 and through January 1, 2026.

The Company has issued restricted stock awards (“RSAs”) under certain legacy option plans that generally vest two to four years based on service conditions. The RSAs began vesting in May 2019, and no additional awards will be issued under this legacy plan.

Share-based Compensation

The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model (“Black-Scholes”). Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period.

The assumptions used in the Black-Scholes model during the six months ended June 30, 2023 and 2022 are presented below.

	Six months ended
	June 30, 2023	June 30, 2022
Risk-free interest rate	3.54% - 4.20%	2.65% - 3.52%
Expected volatility	90.99% - 91.58%	84.81% - 85.67%
Expected term (in years)	5.50 - 7.00	5.50 - 7.00
Expected dividend yield	0%	0%

The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based on the historical volatility of Armata and peer companies’ common stock. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the SEC Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. For stock options granted to parties other than employees or directors, the Company elects, on a grant-by-grant basis, to use the expected term or the contractual term of the option award. The Company has never declared or paid dividends on its Common Stock and has no plans to do so in the foreseeable future. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

The tables below summarize the total share-based compensation expense included in the Company’s consolidated statements of operations for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Research and development	$	259,000	$	489,000	$	804,000	$	679,000
General and administrative		2,000		460,000		314,000		763,000
Total share-based compensation	$	261,000	$	949,000	$	1,118,000	$	1,442,000

19

Stock option transactions during the six months ended June 30, 2023 are presented below:

	Options Outstanding
				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Term	Intrinsic
	Shares	Price		(Years)	Value
Outstanding at December 31, 2022	3,352,803	$	5.32	7.8
Granted	17,500		2.36
Exercised	—		—		$	—
Forfeited/Cancelled	(168,374)		5.63
Outstanding at June 30, 2023	3,201,929	$	5.29	7.3	$	—
Vested and expected to vest at June 30, 2023	3,201,929	$	5.29	6.7	$	—
Exercisable at June 30, 2023	2,142,829	$	5.57	7.3	$	—

Restricted stock award transactions under the Assumed 2016 Plan and restricted stock unit award transactions during the six months ended June 30, 2023 are presented below:

		Weighted Avg
		Grant Date
	Shares	Fair Value
Outstanding at December 31, 2022	129,666	$	27.11
Granted	—		—
Forfeited/Cancelled	(3,699)		39.54
Vested and Issued as Common Stock	(54,901)		29.97
Outstanding at June 30, 2023	71,066	$	24.25

The aggregate intrinsic value of options at June 30, 2023 is based on the Company’s closing stock price on that date of $1.14 per share. As of June 30, 2023, there was $1.7 million of total unrecognized compensation expense related to unvested stock options and RSAs, which the Company expects to recognize over the weighted average remaining period of approximately 1.78 years.

Shares Reserved for Future Issuance

As of June 30, 2023, the Company had reserved shares of its Common Stock for future issuance as follows:

	Shares Reserved
Stock options outstanding	3,201,929
Unvested restricted stock units	71,066
Employee stock purchase plan	9,748
Available for future grants under the 2016 Plan	2,534,180
Warrants outstanding	20,549,338
Total shares reserved	26,366,261

10. Income Taxes

The Company did not record a provision or benefit for income taxes during the three and six months ended June 30, 2023 and 2022. As of both June 30, 2023 and December 31, 2022, the Company continues to maintain a full valuation allowance against all of its deferred tax assets in light of its history of cumulative losses.

20

11. Commitments and Contingencies

Operating Leases

The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced January 1, 2012 and in April 2020, the Company amended the lease (“2020 Lease Amendment”) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, will be approximately $1.9 million, and base rent increases by 3% annually and will be $2.5 million by the end of the amended term. In addition, the Company received a six-month rent abatement in 2020. The Company did not use an allowance for tenant improvements of $0.8 million during 2021, which will offset rent payments as prescribed by the 2020 Lease Amendment starting in 2022. In accordance with authoritative guidance, the Company re-measured the lease liability in April 2020 to be $11.7 million and related right of use asset of $11.0 million as of the Lease Amendment date with an incremental borrowing rate of 12.89%.

Concurrent with the Company’s execution of the 2020 Lease Amendment, an irrevocable letter of credit in the amount of $1.2 million was delivered to the landlord. Starting on February 1, 2022, and each year thereafter, the letter of credit will be reduced by 20% of the then outstanding amount.

On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the “2021 Lease”). The 2021 Lease payment start date is May 1, 2022 and the total lease term is for 16 years and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately $0.25 million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to $7.3 million, and the Company is responsible for construction costs over such allowance. Out of pocket expenses to be incurred by the Company are considered noncash lease payments, and included in the lease liability and right-of-use asset when the amount can be reasonably estimated. As of November 16, 2022, the Company finalized the budget to complete the construction of the 2021 Lease. Accordingly, the Company re-measured the lease liability and related right-of-use asset as of November 30, 2022, using an incremental borrowing rate of 11.8%. The re-measured lease liability of the 2021 Lease as of November 16, 2022 was $37.0 million, and the related right of use asset was $33.8 million. During the three months ended June 30, 2023, the budget was modified and the Company re-measured the lease liability as of April 30, 2023, and increased the lease liability and related right-of-use asset by approximately $1.0 million, using an incremental borrowing rate of 14.27%.

In connection with the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the total amount of $5.0 million to the landlord in 2022.

Legal Proceedings

From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company’s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company’s consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company’s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

21

12. Grants and Awards

MTEC Grant

On June 15, 2020, the Company entered into a Research Project Award agreement (the “MTEC Agreement”) with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which the Company received a $15.0 million grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase 1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections. The MTEC Agreement specifies that the grant will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC.

Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.

The MTEC Agreement is effective through October 30, 2024. The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.

The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue on the statement of operations when related costs are incurred. The Company recognized $1.0 million and $1.8 million in grant revenue from the MTEC Agreement during the three and six months ended June 30, 2023, respectively. The Company recognized $1.9 million and $3.1 million in grant revenue from the MTEC Agreement during the three and six months ended June 30, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company had $0.2 million and $1.6 million as unbilled awards receivable from MTEC, respectively.

CFF Therapeutics Development Award

On March 13, 2020, the Company entered into an award agreement (the “Award Agreement”) with CFF, pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the “CFF Award”). The CFF Award will be used to fund a portion of the Company’s Phase 1b/2a clinical trial of the Pseudomonas aeruginosa (“P. aeruginosa”) phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (“CF”).

The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the CFF Award will be paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement.

If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an “Interruption”) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the “CF Field”), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.

22

Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.

The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company’s material failure to achieve certain development milestones. The Company’s payment obligations survive the termination of the Award Agreement.

The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. No credits were recognized during the three and six months ended June 30, 2023 or 2022. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.

23

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report, and our audited financial statements and notes thereto as of and for the year ended December 31, 2022 included in our Annual Report on Form 10-K filed on March 16, 2023 with the U.S. Securities and Exchange Commission (the “SEC”).

Our common stock is traded on the NYSE American exchange under the symbol “ARMP.” We are currently headquartered in Los Angeles, CA, and we have a research and development facility for product development to support advancing phage products from the bench to the clinic. In addition to microbiology, synthetic biology, formulation, chemistry and analytical laboratories, the facility is equipped with two licensed current good manufacturing practice (“cGMP”) drug manufacturing suites enabling the production, testing and release of clinical trial material.

Statements contained in this Quarterly Report that are not statements of historical fact are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements concerning product development plans, commercialization of our products, the expected market opportunity for our products, the use of bacteriophages and synthetic phages to kill bacterial pathogens, having resources sufficient to fund our operations into the third quarter of 2023, future funding sources, general and administrative expenses, clinical trial and other research and development expenses, costs of manufacturing, costs relating to our intellectual property, capital expenditures, the expected benefits of our targeted phage therapies strategy, the potential market for our products, tax credits and carry-forwards, and litigation-related matters. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These statements are subject to risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 16, 2023 with the SEC, and under Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. These forward-looking statements speak only as of the date on which they were made, and we undertake no obligation to update any forward-looking statements.

Overview

We are a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using our proprietary bacteriophage-based technology. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing specific bacteria, including those forming biofilms, in contrast to traditional broad-spectrum antibiotics. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current standard of care therapies, including the so-called multidrug-resistant or “superbug” strains of bacteria. We are a leading developer of phage therapeutics administered intravenously as well as locally, and are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.

We are combining our proprietary approach and unique purification procedures and expertise in identifying, characterizing and developing both naturally-occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific cGMP capabilities to advance a broad pipeline of high-quality multi-bacteriophage product candidates that can be tolerated no matter the route of deliverer from intravenously, topically and inhaled.

We are developing and advancing the clinical phage candidate, AP-PA02, for Pseudomonas aeruginosa (“P. aeruginosa”). On October 14, 2020, we received the approval to proceed from the FDA for our IND application for AP-

24

PA02-101, which was a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (“SAD”) and multiple ascending dose (“MAD”) clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with cystic fibrosis (“CF”) and chronic pulmonary P. aeruginosa infection. In the first quarter of 2023, Armata announced positive topline results from the completed “SWARM-P.a.” study. Data indicated that multiple days of inhaled AP-PA02 was well-tolerated with a treatment emergent adverse event (TEAE) profile similar to placebo. Only mild, self-limited adverse events possibly related to study drug were reported in a few CF subjects. Pharmacokinetic findings confirm that AP-PA02 can be effectively delivered to the lungs through nebulization with minimal systemic exposure. SAD and MAD resulted in a proportional increase in exposure as measured in induced sputum. Additionally, achieved exposures were relatively consistent from subject to subject. Bacterial levels of P. aeruginosa in the sputum were measured at several time points and compared to baseline levels prior to study drug administration. Trends suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at end of treatment as compared to placebo after ten days of dosing. Pharmacokinetic/Pharmacodynamic analysis indicates significant microbiological impacts in the subjects with highest exposures. Importantly, for subjects with the highest average exposure of susceptible phage, there was durability of approximately two-log reduction from end of treatment to end of study (day 28 post dose). This study is supported by the Cystic Fibrosis Foundation (“CFF”), which granted Armata a Therapeutics Development Award of up to $5.0 million.

A key advantage of Armata’s phage manufacturing expertise is the purity profiles of our phage products, including AP-SA02, our phage product candidate for Staphylococcus aureus (“S. aureus”); this has enabled Armata to pursue treatment of complicated S. aureus bacteremia, where repetitive intravenous dosing is required. On June 15, 2020, the Company entered into a Research Project Award agreement (the “MTEC Agreement”) with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which the Company received a $15.0 million grant and entered into a three-year program administered by the U.S. Department of Defense (the “DoD”) through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase 1b/2a, multi-center, randomized, double-blind, placebo- controlled dose escalation study that will assess the safety, tolerability, and efficacy of our phage-based candidate, AP-SA02, for the treatment of adults with complicated S. aureus bacteremia. On November 17, 2021, Armata announced that it had received from the FDA the approval to proceed for our Investigational New Drug application for AP-SA02, and in May 2022, the Company dosed the first patient in the Phase 1b/2a trial (“diSArm” study). The Phase 1b part of the study has been fully enrolled as planned, and the Company anticipates initiation of the Phase 2a part of the study in the third quarter of 2023.

On February 22, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-PA02, in a second indication, NCFB (non-cystic fibrosis bronchiectasis). We initiated a Phase 2 trial (“Tailwind”) in NCFB in 2022 and reported first patient dosing in the first quarter of 2023. The “Tailwind” study is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 phage therapeutic in subjects with NCFB and chronic pulmonary Pseudomonas aeruginosa infection.

On August 1, 2022, Armata announced that it had received from the FDA the approval to proceed for our IND application for AP-SA02, in a second indication, PJI (periprosthetic joint infection). With progress made in the Phase 1b bacteremia study we are proceeding with the second application. We are advancing start-up activities for a Phase 1b/2a trial that will assess the safety and tolerability of intravenous and intra-articular AP-SA02 as an adjunct to standard of care antibiotics in adults undergoing debridement, antibiotics, and implant retention for the treatment of periprosthetic joint infections caused by S. aureus.

We are committed to conducting randomized controlled clinical trials required for FDA approval in order to move toward the commercialization of alternatives to traditional antibiotics and provide a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.

25

The following chart summarizes the status of our phage product candidate development programs and partners.

We have incurred net losses since our inception and our operations to date have been primarily limited to research and development and raising capital. As of June 30, 2023, we had an accumulated deficit of $257.5 million. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and seeking to obtain regulatory approval of our product candidates.

We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates and for working capital and other general corporate purposes. We expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.

We may also use a portion of our existing cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. Our existing cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through one or more other public or private equity offerings, debt financings, collaboration, strategic financing, grants or government contract awards, licensing arrangements or other sources. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and potential disruptions to, and volatility in, financial markets in the United States and worldwide. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of assets, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations and result in a loss of investment by our shareholders.

Recent Events

2023 Credit Agreement

On July 11, 2023, we announced that we had entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder, on July 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025. Repayment of the Loan is guaranteed by our domestic subsidiaries, and the Loan is secured by substantially all of our assets and our subsidiary guarantors.

The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan

26

documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from our operating budget.

2023 Convertible Credit Agreement

On January 10, 2023, we entered into, as borrower, a secured convertible credit and security agreement (the “Convertible Credit Agreement”) with Innoviva. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Convertible Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024. Concurrently with the execution of the Credit Agreement, we entered into an amendment to that certain secured convertible credit and security agreement (the “First Amendment to Convertible Credit Agreement”). Pursuant to the First Amendment to Convertible Credit Agreement, the parties agreed to, among other things, extend the maturity date from January 10, 2024 to January 10, 2025.

Repayment of the Convertible Loan is guaranteed by our domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of our assets and the subsidiary guarantors.

The Convertible Credit Agreement provides that if a Qualified Financing, as defined in the Convertible Credit Agreement, occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Convertible Loan shall be converted into shares of our common stock, par value $0.01 per share (“Common Stock”) at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event). The Convertible Credit Agreement also required us to file a registration statement (the “Registration Statement”) for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender’s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).

Results of Operations

Comparison of three and six months ended June 30, 2023 and 2022

	Three Months Ended				Change
	June 30, 2023		June 30, 2022		Amount		%
Grant revenue	$	980,000	$	1,883,000	$	(903,000)		(48.0)%
Operating expenses
Research and development		8,259,000		9,020,000		(761,000)		(8.4)%
General and administrative		2,350,000		2,083,000		267,000		12.8%
Total operating expenses		10,609,000		11,103,000		(494,000)		(4.4)%
Loss from operations		(9,629,000)		(9,220,000)		(409,000)		4.4%
Other income (expense)
Interest income		46,000		5,000		41,000		820.0%
Change in fair value of convertible debt		6,036,000		—		6,036,000		100.0%
Total other income (expense), net		6,082,000		5,000		6,077,000		121540%
Net loss	$	(3,547,000)	$	(9,215,000)	$	5,668,000		(61.5)%

27

	Six Months Ended				Change
	June 30, 2023		June 30, 2022		Amount		%
Grant revenue	$	1,776,000	$	3,119,000	$	(1,343,000)		(43.1)%
Operating expenses
Research and development		17,863,000		17,048,000		815,000		4.8%
General and administrative		4,888,000		4,066,000		822,000		20.2%
Total operating expenses		22,751,000		21,114,000		1,637,000		7.8%
Loss from operations		(20,975,000)		(17,995,000)		(2,980,000)		16.6%
Other income (expense)
Interest income		64,000		6,000		58,000		966.7%
Change in fair value of convertible debt		2,874,000		—		2,874,000		100.0%
Total other income (expense), net		2,938,000		6,000		2,932,000		48867%
Net loss	$	(18,037,000)	$	(17,989,000)	$	(48,000)		0.3%

Grant Revenue

The Company recognized $1.0 million and $1.9 million of grant revenue during the three months ended June 30, 2023 and 2022, and $1.8 million and $3.1 million of grant revenue during the six months ended June 30, 2023 and 2022, respectively, which represents MTEC’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia.

Research and Development

Research and development expenses for the three months ended June 30, 2023 and 2022 were $8.3 million and $9.0 million, respectively. The decrease of $0.7 million was primarily related to a decrease of $0.7 million related to decreased clinical trial activities and laboratory supplies expenses, a decrease of $0.3 million in personnel costs, offset by an increase of $0.3 million in lease and professional services expenses.

Research and development expenses for the six months ended June 30, 2023 and 2022 were $17.9 million and $17.0 million, respectively. The increase of $0.9 million was primarily related to an increase of $0.5 million in personnel costs, a $0.7 million increase in professional services, $0.4 million increase in lease expenses, and offset by a $0.7 million decrease in clinical trial activities and laboratory supplies expenses.

General and Administrative

General and administrative expenses were $2.4 million and $2.1 million for the three ended June 30, 2023 and 2022, respectively. The increase of $0.3 million is primarily related to a $0.6 million increase in legal and professional expenses, and $0.1 million of increase in lease expenses, offset by a decrease of $0.4 million in personnel costs.

General and administrative expenses were $4.9 million and $4.1 million for the six months ended June 30, 2023 and 2022, respectively. The increase of $0.8 million is primarily related to a $1.0 million increase in legal and professional expenses, offset by a $0.2 million decrease in personnel expenses.

Other Income (Expense)

For the three and six months ended June 30, 2023, we recorded other income due to change in our Convertible Loan from Innoviva, which is recorded at fair value in its entirety, of $6.0 million and $2.9 million, respectively.

Income Taxes

There was no income tax expense or benefit for the three and six months ended June 30, 2023 and 2022.

28

Operating Activities

Net cash used in operating activities for the six months ended June 30, 2023 was $29.6 million, as compared to $11.7 million for the six months ended June 30, 2022. The increase of $17.9 million in cash used for operating activities was primarily due to an increase of $14.8 million in cash used for operating assets and liabilities including payments made under our operating lease arrangements and prepayments for clinical activities, and offset by decreases of $3.1 million related to non-cash reconciling items from net loss to cash used in operating activities.

Investing Activities

Net cash used in investing activities was $2.2 million and $1.4 million for the three and six months ended June 30, 2023 and 2022, respectively, and primarily related to purchases of laboratory equipment.

Financing Activities

Net cash provided by financing activities was $29.2 million for the six months ended June 30, 2023, which was primarily comprised of $29.2 million of proceeds raised from the convertible debt issued to Innoviva, net of issuance costs.

Net cash provided by financing activities was $44.5 million for the six months ended June 30, 2022, which was comprised of $44.4 million of net proceeds raised from the February 2022 private placement transactions with Innoviva, and $0.1 million of proceeds for exercise of stock options.

Liquidity, Capital Resources and Financial Condition

We have prepared our condensed consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception and have negative operating cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. We may not be able to secure additional financing in a timely manner or on favorable terms, if at all.

As of June 30, 2023, we had cash and cash equivalents of $12.5 million. Management believes that our current cash resources, along with the funds received in the $25.0 million Loan financing that closed in July 2023, will be sufficient to fund the Company’s planned operations into the first quarter of 2024. For the foreseeable future, our ability to continue our operations is dependent upon our ability to obtain additional capital.

Future Capital Requirements

We will need to raise additional capital in the future to continue to fund our operations. Our future funding requirements will depend on many factors, including:

● the costs and timing of our research and development activities;

● the progress and cost of our clinical trials and other research and development activities;

● manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;

● the costs of completing the construction and improvements of our leased premises to be used as our new headquarters. As of June 30, 2023, the total projected construction costs of our new leased headquarter in Los

29

Angeles was estimated to be approximately $26.5 million, inclusive of $7.3 million reimbursable from the landlord, and of which $15.7 million have been incurred to date. The estimated total construction costs may change as the project progresses;

● the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;

● whether and when we receive future Australian tax rebates, if any;

● the costs and timing of seeking regulatory approvals;

● the costs of filing, prosecuting and enforcing any patent applications, claims, patents and other intellectual property rights; and

● the costs of potential lawsuits involving us or our product candidates.

We may seek to raise capital through a variety of sources, including:

● the public equity market;

● private equity financings;

● collaborative arrangements, government grants or strategic financings;

● licensing arrangements; and

● public or private debt.

Any additional fundraising efforts may divert our management team from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on acceptable terms. If we are unable to secure additional funds on a timely basis or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our shareholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations. Moreover, if we are unable to obtain additional funds on a timely basis, there will be substantial doubt about our ability to continue as a going concern and increased risk of insolvency and loss of investment by our shareholders. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities could result in dilution to our existing shareholders. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide.

Off-Balance Sheet Arrangements

As of June 30, 2023, we did not have off-balance sheet arrangements.

30

Critical Accounting Policies and Estimates

Management’s discussion and analysis of financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to fair value of our convertible debt, the allowance for doubtful accounts, useful lives of intangible assets, recoverability of the carrying amounts of goodwill and intangible assets, share-based compensation and income tax provision. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Refer to Note 3 to the condensed consolidated financial statements contained elsewhere in this report. During the three and six months ended June 30, 2023, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K filed with the SEC on March 16, 2023.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial and Accounting Officer), of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this quarterly report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2023.

Changes in Internal Control over Financial Reporting

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting; however, that evaluation is ongoing and because of its ongoing nature, there can be no assurance that we will not identify any change that would materially affect, or be reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints,

31

and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we are a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business. We intend to vigorously defend our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.

Item 1A. RISK FACTORS

Our business is subject to a number of risks, including those identified in Item 1A of Part I of our 2022 Form 10-K. There have been no material changes to the risk factors described in our 2022 Form 10-K.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On July 10, 2023, we entered into an amendment with Innoviva (the “First Amendment to Second A&R Voting Agreement”) to the Second Amended and Restated Voting Agreement (“Voting Agreement”), dated as of February 9, 2022, by and among us and Innoviva to extend the expiration date of the Voting Agreement to the earlier of the fifth anniversary of the effective date, or February 9, 2027, and the date of receipt of approval by the U.S. Food and Drug Administration of any of our product candidates for marketing and commercial distribution.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

None.

32

Item 6. EXHIBITS

Number		Description
3.1	Amended and Restated Articles of Incorporation of the Company, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 16, 2015).
3.2	Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-37544), filed with the SEC on April 24, 2017.
3.3	Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on November 8, 2018).
3.4	Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 18, 2018).
3.5	Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 10, 2019).
3.6	Articles of Amendment to Amended and Restated Articles of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on December 11, 2019).
3.7	Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 30, 2020).
3.8	Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).
3.9	Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on December 11, 2019).
3.10	Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 26, 2020).
4.1	Reference is made to Exhibits 3.1 through 3.4.
10.1	Secured Convertible Credit and Security Agreement, dated January 10, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 10, 2023).
10.2	Registration Rights Agreement, dated as of February 9, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 4.21 to the Company’s Registration Statement on Form S-3, filed with the SEC on February 13, 2023).
10.3		Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 11, 2023).

33

10.4	First Amendment to Security Convertible Credit and Security Agreement, dated as of July 10, 2023, by and between the Company and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on July 11, 2023).
10.5	Amendment No. 1 to the Second Amended and Restated Voting Agreement, dated as of July 10, 2023, by and between the Company, Innoviva, Inc. and Innoviva Strategic Opportunities LLC (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on July 11, 2023).
10.6	Offer Letter of Employment, by and between the Company and Dr. Deborah Birx (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on July 11, 2023).
31.1	Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
31.2	Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
32.1†	Certification of Principal Executive Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.
32.2†	Certification of Principal Financial Officer Required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
104	Cover Page Interactive Data File Cover Page Interactive Data File (embedded within the Inline XBRL document)

^† The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

34

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ARMATA PHARMACEUTICALS, INC.
Date: August 14, 2023		By	/s/ Deborah L. Birx
			Name: Deborah L. Birx, M.D.
			Title: Chief Executive Officer
			(Principal Executive Officer)
		By	/s/ Julianne Averill
			Name: Julianne Averill
			Title: Chief Financial Officer
			(Principal Financial and Accounting Officer)

35

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Deborah L. Birx, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Armata Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2023

/s/ Deborah L. Birx

Deborah L. Birx, M.D.

Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Julianne Averill, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Armata Pharmaceuticals, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2023

/s/ Julianne Averill

Julianne Averill

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Armata Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Deborah L. Birx, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: August 14, 2023

/s/ Deborah L. Birx

Deborah L. Birx, M.D.

Chief Executive Officer

(Principal Executive Officer)

EX-32.2

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Armata Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Julianne Averill, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: August 14, 2023

/s/ Julianne Averill

Julianne Averill

Chief Financial Officer

(Principal Financial and Accounting Officer)

XML

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Entity File Number	001-37544
Entity Registrant Name	ARMATA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	WA
Entity Tax Identification Number	91-1549568
Entity Address, Address Line One	5005 McConnell Avenue
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90066
City Area Code	310
Local Phone Number	665-2928
Title of 12(b) Security	Common Stock
Trading Symbol	ARMP
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		36,127,306
Entity Central Index Key	0000921114
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 12,456,000	$ 14,852,000
Prepaid expenses	5,745,000	3,664,000
Other receivables	8,633,000	8,531,000
Total current assets	26,834,000	27,047,000
Restricted cash	5,720,000	5,960,000
Property and equipment, net	8,807,000	3,617,000
Operating lease right-of-use asset	43,652,000	43,035,000
In-process research and development	10,256,000	10,256,000
Goodwill	3,490,000	3,490,000
Other assets	2,453,000	2,429,000
Total assets	101,212,000	95,834,000
Current liabilities
Accounts payable and accrued liabilities	9,584,000	6,034,000
Accrued compensation	1,098,000	1,828,000
Current portion of operating lease liabilities	14,528,000	17,011,000
Convertible debt	26,352,000
Total current liabilities	51,562,000	24,873,000
Operating lease liabilities, net of current portion	27,430,000	31,804,000
Deferred tax liability	3,077,000	3,077,000
Total liabilities	82,069,000	59,754,000
Stockholders' equity
Common stock, $0.01 par value; 217,000,000 shares authorized; 36,127,306 and 36,144,706 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	361,000	361,000
Additional paid-in capital	276,593,000	275,493,000
Accumulated deficit	(257,811,000)	(239,774,000)
Total stockholders' equity	19,143,000	36,080,000
Total liabilities and stockholders' equity	$ 101,212,000	$ 95,834,000

XML

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Condensed Consolidated Balance Sheets
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	217,000,000	217,000,000
Common stock, shares issued	36,127,306	36,144,706
Common stock, shares outstanding	36,127,306	36,144,706

XML

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Condensed Consolidated Statements of Operations
Grant revenue	$ 980,000	$ 1,883,000	$ 1,776,000	$ 3,119,000
Operating expenses
Research and development	8,259,000	9,020,000	17,863,000	17,048,000
General and administrative	2,350,000	2,083,000	4,888,000	4,066,000
Total operating expenses	10,609,000	11,103,000	22,751,000	21,114,000
Loss from operations	(9,629,000)	(9,220,000)	(20,975,000)	(17,995,000)
Other income (expense)
Interest income	46,000	5,000	64,000	6,000
Change in fair value of convertible debt	6,036,000		2,874,000
Total other income (expense), net	6,082,000	5,000	2,938,000	6,000
Net loss	$ (3,547,000)	$ (9,215,000)	$ (18,037,000)	$ (17,989,000)
Net Loss per Share
Net loss per share, basic	$ (0.10)	$ (0.26)	$ (0.50)	$ (0.55)
Weighted average shares outstanding, basic	36,068,130	35,999,642	36,056,649	32,517,416
Net loss per share, diluted	$ (0.17)	$ (0.26)	$ (0.50)	$ (0.55)
Weighted average shares outstanding, diluted	56,544,698	35,999,642	36,056,649	32,517,416

XML

Condensed Consolidated Statements of Shareholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balances at Dec. 31, 2021	$ 271,000	$ 227,983,000	$ (202,857,000)	$ 25,397,000
Balances (in shares) at Dec. 31, 2021	27,112,299
Sale of common stock, net of issuance costs	$ 90,000	44,301,000		44,391,000
Sale of common stock, net of issuance costs (in shares)	9,000,000
Return of restricted stock awards for tax withholdings		(21,000)		(21,000)
Return of restricted stock awards for tax withholdings, shares	(5,511)
Forfeiture of restricted stock awards (in shares)	(369)
Exercise of stock options		71,000		71,000
Exercise of stock options (in shares)	21,775
Share-based compensation		1,442,000		1,442,000
Net loss			(17,989,000)	(17,989,000)
Balances at Jun. 30, 2022	$ 361,000	273,776,000	(220,846,000)	53,291,000
Balances (in shares) at Jun. 30, 2022	36,128,194
Balances at Mar. 31, 2022	$ 361,000	272,809,000	(211,631,000)	61,539,000
Balances (in shares) at Mar. 31, 2022	36,112,053
Issuance cost in connection with sale of common stock		(32,000)		(32,000)
Return of restricted stock awards for tax withholdings		(21,000)		(21,000)
Return of restricted stock awards for tax withholdings, shares	(5,511)
Forfeiture of restricted stock awards (in shares)	(123)
Exercise of stock options		71,000		71,000
Exercise of stock options (in shares)	21,775
Share-based compensation		949,000		949,000
Net loss			(9,215,000)	(9,215,000)
Balances at Jun. 30, 2022	$ 361,000	273,776,000	(220,846,000)	53,291,000
Balances (in shares) at Jun. 30, 2022	36,128,194
Balances at Dec. 31, 2022	$ 361,000	275,493,000	(239,774,000)	36,080,000
Balances (in shares) at Dec. 31, 2022	36,144,706
Return of restricted stock awards for tax withholdings, shares	(3,699)
Forfeiture of restricted stock awards		(18,000)		(18,000)
Forfeiture of restricted stock awards (in shares)	(13,701)
Share-based compensation		1,118,000		1,118,000
Net loss			(18,037,000)	(18,037,000)
Balances at Jun. 30, 2023	$ 361,000	276,593,000	(257,811,000)	19,143,000
Balances (in shares) at Jun. 30, 2023	36,127,306
Balances at Mar. 31, 2023	$ 361,000	276,350,000	(254,264,000)	22,447,000
Balances (in shares) at Mar. 31, 2023	36,144,706
Return of restricted stock awards for tax withholdings		(18,000)		(18,000)
Return of restricted stock awards for tax withholdings, shares	(13,701)
Forfeiture of restricted stock awards (in shares)	(3,699)
Share-based compensation		261,000		261,000
Net loss			(3,547,000)	(3,547,000)
Balances at Jun. 30, 2023	$ 361,000	$ 276,593,000	$ (257,811,000)	$ 19,143,000
Balances (in shares) at Jun. 30, 2023	36,127,306

XML

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (18,037,000)	$ (17,989,000)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	458,000	421,000
Share-based compensation	1,118,000	1,442,000
Change in fair value of convertible debt	(2,874,000)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities	116,000	1,622,000
Accrued compensation	(730,000)	621,000
Operating lease right-of-use asset and liability, net	(7,474,000)	1,781,000
Prepaid expenses and other current assets	(2,207,000)	439,000
Net cash used in operating activities	(29,630,000)	(11,663,000)
Investing activities:
Purchases of property and equipment	(2,232,000)	(1,372,000)
Net cash used in investing activities	(2,232,000)	(1,372,000)
Financing activities:
Proceeds from issuance of convertible debt, net of issuance costs	29,226,000
Proceeds from sale of common stock, net of offering costs		44,414,000
Proceeds from exercise of warrants and stock options		71,000
Net cash provided by financing activities	29,226,000	44,485,000
Net increase in cash, cash equivalents and restricted cash	(2,636,000)	31,450,000
Cash, cash equivalents and restricted cash, beginning of period	20,812,000	11,488,000
Cash, cash equivalents and restricted cash, end of period	18,176,000	42,938,000
Supplemental disclosure of cash flow information:
Unpaid offering costs		23,000
Property and equipment included in accounts payable	$ 3,416,000	$ 85,000

XML

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	$ 12,456,000	$ 14,852,000	$ 36,978,000
Restricted cash	5,720,000	5,960,000	5,960,000
Cash, cash equivalents and restricted cash	$ 18,176,000	$ 20,812,000	$ 42,938,000	$ 11,488,000

XML

Organization and Description of the Business

6 Months Ended

Jun. 30, 2023

Organization and Description of the Business

Organization and Description of the Business

1. Organization and Description of the Business

Armata Pharmaceuticals, Inc. (“Armata”), and together with its subsidiaries, is referred to herein as, the “Company”, is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata’s common stock is traded on the NYSE American exchange under the ticker symbol “ARMP”.

XML

Liquidity

6 Months Ended

Jun. 30, 2023

Liquidity

Liquidity

2. Liquidity

The Company has prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.

2023 Credit Agreement

On July 10, 2023, the Company entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder of the Company on July 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025. Repayment of the Loan is guaranteed by the Company’s domestic subsidiaries, and the Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

The Credit Agreement contains customary affirmative and negative covenants and representations and warranties, including financial reporting obligations and certain limitations on indebtedness, liens, investments, distributions (including dividends), collateral, investments, mergers or acquisitions and fundamental corporate changes. The Credit Agreement also includes customary events of default, including payment defaults, breaches of provisions under the loan documents, certain losses or impairment of collateral and related security interests, the occurrence of certain events that could reasonably be expected to have a “material adverse effect” as set forth in the Credit Agreement, certain bankruptcy or insolvency events, and a material deviation from the Company’s operating budget.

2023 Convertible Credit Agreement

On January 10, 2023, the Company entered into, as borrower, a secured convertible credit and security agreement (the “Convertible Credit Agreement”) with Innoviva. The Convertible Credit Agreement provides for a secured term loan facility in an aggregate amount of $30 million (the “Convertible Loan”) at an interest rate of 8.0% per annum, and has a maturity date of January 10, 2024. Concurrently with the execution of the Credit Agreement, the Company entered into an amendment to that certain secured convertible credit and security agreement (the “First Amendment to Convertible Credit Agreement”). Pursuant to the First Amendment to Convertible Credit Agreement, the parties agreed to, among other things, extend the maturity date from January 10, 2024 to January 10, 2025.

Repayment of the Convertible Loan is guaranteed by the Company’s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

 The Convertible Credit Agreement provides that if a Qualified Financing (as defined in the Credit Agreement) occurs, the outstanding principal amount of, and all accrued and unpaid interest on, the Convertible Loan shall be converted into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by investors in a Qualified Financing (which price paid by investors in a Qualified Financing may not be less than a 15.0% discount to the closing price of Common Stock immediately prior to the consummation of a Qualified Financing event). The Convertible Credit Agreement also required the Company to file a registration statement (the “Registration Statement”) for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender’s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).

2022 Equity Financing

On February 9, 2022, the Company entered into a securities purchase agreement (“February 2022 Securities Purchase Agreement”) to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase 9,000,000 newly issued shares of the Company’s Common Stock, at a price of $5.00 per share, and warrants to purchase up to 4,500,000 additional shares of Common Stock, with an exercise price of $5.00 per share. The stock purchases closed in two tranches. On February 9, 2022, Innoviva purchased 3,614,792 shares of common stock and warrants to purchase 1,807,396 shares of Common Stock for an aggregate purchase price of approximately $18.1 million. At the closing of the second tranche, following the Company’s shareholders voting in favor of the transaction on March 30, 2022, Innoviva purchased 5,385,208 shares of Common Stock and warrants to purchase 2,692,604 shares of Common Stock for an aggregate purchase price of $26.9 million on March 31, 2022.

As of June 30, 2023, the Company had cash and cash equivalents of $12.5 million. The Company’s current cash resources, along with the funds received in the Loan financing closed in July 2023, that management believes will be sufficient to fund the Company’s planned operations into the first quarter of 2024. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital.

Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing shareholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing shareholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected.

XML

Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies

Significant Accounting Policies

3. Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed

consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2022 included in the Company’s Form 10-K, filed with the SEC on March 16, 2023. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company’s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.

In-Process Research and Development (“IPR&D”)

IPR&D assets are intangible assets with indefinite lives and are not subject to amortization. The Company’s IPR&D assets represent capitalized incomplete research projects acquired by the Company, which is related to the development of natural phage combinations for the treatment of Staphylococcus aureus infections (“S. aureus”), examples of which comprise AP-SA01 and AP-SA02. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.

Goodwill

Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company’s consolidated statements of operations.

Basic and Diluted Net Loss per Share

Net earnings or loss per share (“EPS”) is calculated in accordance with the applicable accounting guidance provided in ASC 260, Earnings per Share. The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common shareholders. The two-class method is an earnings allocation

formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.

Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.  Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method.

The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common shareholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

Grants and Awards

In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a “customer”, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (“ASC 808”). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.

Armata also considers the guidance in ASC Topic 730, Research and Development (“ASC 730”), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability. If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.

Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.

Leases

The Company determines if an arrangement contains a lease at inception. The Company currently only has operating leases. The Company recognizes a right-of-use operating lease asset and associated short and long-term operating lease liability on its condensed consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liabilities represent the Company’s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term. The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised.

As the Company’s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available on the date of adoption of Topic 842, Leases, as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.

Research and Development Expenses

Research and development (“R&D”) costs consist primarily of direct and allocated salaries, incentive compensation, share-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.

Reclassifications

Certain prior year amounts, including tenant improvement receivable and awards receivable, have been reclassified to conform to the current year presentation. Refer to Note 6 Other Receivables table for details.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023 which did not have an impact on its consolidated financial statements or related disclosures.

In August 2020, the FASB issued ​ASU 2020-06​, ​Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)​ (“ASU 2020-06”). ​ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company’s consolidated financial statements.

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2023

Fair Value Measurements

Fair Value Measurements

4. Fair Value Measurements

The Company's Convertible Loan (Note 7) is measured at fair value, which is revalued at each measurement period.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following three levels:

●Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

●Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

●Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company estimates the fair value of its Convertible Loan (Note 7) using a weighted probability of various scenario of the Convertible Loan during its term, utilizing significant assumptions and estimates such as volatility and risk-free interest rates, which are level 3 fair value inputs unobservable from active markets.

The following table presents the Company’s fair value measurements using level 3 inputs during the three and six months ended June 30, 2023.

	Fair Value
Balance at December 31, 2022	$	—
Net issuance of the Convertible Loan		29,226,000
Change in fair value		3,162,000
Balance at March 31, 2023	$	32,388,000
Change in fair value		(6,036,000)
Balance at June 30, 2023	$	26,352,000

XML

Net Loss per Share

6 Months Ended

Jun. 30, 2023

Net Loss per Share

Net Loss per Share

5. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated:

	Three Months Ended		Six Months Ended
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Basic and diluted net loss per common share calculation:
Net loss attributable to common shareholders - basic	($ 3,547,000)	($ 9,215,000)	($ 18,037,000)	($ 17,989,000)
Change in fair value of convertible debt	6,036,000	—	2,874,000	—
Net loss attributable to common shareholders - diluted	($ 9,583,000)	($ 9,215,000)	($ 20,911,000)	($ 17,989,000)
Weighted average common shares outstanding - basic	36,068,130	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - basic	($ 0.10)	($ 0.26)	($ 0.50)	($ 0.55)
Weighted average common shares outstanding - diluted	56,544,698	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - diluted	($ 0.17)	($ 0.26)	($ 0.50)	($ 0.55)

The following outstanding securities as of June 30, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:

	June 30, 2023	June 30, 2022
Options	3,201,929	3,380,678
Unvested restricted stock units	30,000	30,000
Restricted stock awards	41,066	99,666
Warrants	20,549,338	20,549,338
Total	23,822,333	24,059,682

XML

Balance Sheet Details

6 Months Ended

Jun. 30, 2023

Balance Sheet Details

Balance Sheet Details

6. Balance Sheet Details

Property and Equipment

Property and equipment as of June 30, 2023 and December 31, 2022 consisted of the following:

	June 30, 2023		December 31, 2022
Laboratory and manufacturing equipment	$	15,655,000	$	10,007,000
Furniture and fixtures		817,000		817,000
Office and computer equipment		449,000		449,000
Leasehold improvements		3,447,000		3,447,000
Total		20,368,000		14,720,000
Less: accumulated depreciation		(11,561,000)		(11,103,000)
Property and equipment, net	$	8,807,000	$	3,617,000

Depreciation expense totaled $0.2 million for each of the three months ended June 30, 2023 and 2022, and $0.5 million and $0.4 million for the six months ended June 30, 2023 and 2022, respectively.

Other Receivables

Other receivables as of June 30, 2023 and December 31, 2022 consisted of the following:

	June 30, 2023		December 31, 2022
Tenant improvement receivable	$	7,375,000	$	6,595,000
Awards receivable		1,258,000		1,936,000
	$	8,633,000	$	8,531,000

XML

Convertible Debt

6 Months Ended

Jun. 30, 2023

Convertible Debt

Convertible Debt

7. Convertible Debt

As described in Note 2, on January 10, 2023, the Company received a Convertible Loan of $30 million from Innoviva pursuant to the Convertible Credit Agreement. The Convertible Loan bears an interest rate of 8.0% per annum. The Convertible Loan had a maturity date of January 10, 2024, which was amended to January 10, 2025 in connection with the First Amendment to Convertible Credit Agreement entered into between the Company and Innoviva on July 10, 2023. Repayment of the Convertible Loan is guaranteed by the Company’s domestic subsidiaries and foreign material subsidiaries, and the Convertible Loan is secured by substantially all of the assets of the Company and the subsidiary guarantors.

 The Convertible Credit Agreement provides that if a Qualified Financing occurs, which is defined in the Convertible Credit Agreement as a financing from new investors of at least $30 million, the outstanding principal amount of and all accrued and unpaid interest on the Convertible Loan shall be converted into shares of the Company’s common stock, at a price per share equal to a 15.0% discount to the lowest price per share for Common Stock paid by

investors in such Qualified Financing. The Convertible Credit Agreement also required the Company to file the Registration Statement for the resale of all securities issued to the lender in connection with any conversion under the Convertible Credit Agreement, which the Company originally filed on February 13, 2023 and which was declared effective by the SEC on April 6, 2023. The Convertible Credit Agreement also confers upon the lender the option to convert any outstanding Convertible Loan amount, including all accrued and unpaid interest thereon, at the lender’s option, into shares of Common Stock at a price per share equal to the greater of book value or market value per share of Common Stock on the date immediately preceding the effective date of the Convertible Credit Agreement, which was $1.52 (as may be appropriately adjusted for any stock split, combination or similar act).

The Company evaluated authoritative guidance for accounting for the Convertible Loan and concluded that the Convertible Loan should be accounted for at fair value under ASC 480, Distinguish Liabilities from Equity, due to the fact that the Convertible Loan will predominately be settled with the Company’s Common Stock. Consequently, the Company recorded the Convertible Loan in its entirety at fair value on its balance sheet, with changes in fair value recorded as other income (expenses) in the statement of operations during each reporting period.

XML

Stockholders' Equity

6 Months Ended

Jun. 30, 2023

Stockholders' Equity

Stockholders' Equity

8. Shareholders’ Equity

Private Investment

February 2022 Private Placement

On February 9, 2022, the Company entered into the February 2022 Securities Purchase Agreement to sell its Common Stock and warrants to Innoviva. Pursuant and subject to the terms and conditions of the February 2022 Securities Purchase Agreement and related agreements, Innoviva agreed to purchase 9,000,000 newly issued shares of the Company’s Common Stock, at a price of $5.00 per share, and warrants to purchase up to 4,500,000 additional shares of Common Stock, with an exercise price of $5.00 per share. The stock purchases occurred in two tranches. On February 9, 2022, Innoviva purchased 3,614,792 shares of Common Stock and warrants to purchase 1,807,396 shares of Common Stock for an aggregate purchase price of approximately $18.1 million. On March 31, 2022, upon the Company’s shareholders voting in favor of the transaction, Innoviva purchased 5,385,208 shares of Common Stock and warrants to purchase 2,692,604 shares of Common Stock for an aggregate purchase price of $26.9 million.

Warrants issued to Innoviva expire five years from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity.

Warrants

On June 30, 2023, outstanding warrants to purchase shares of Common Stock are as follows:

Shares Underlying Outstanding Warrants	Exercise Price		Expiration Date
1,183,491	$	5.60	October 16, 2023
993,139	$	2.87	February 11, 2025
7,717,661	$	2.87	March 27, 2025
1,867,912	$	3.25	January 26, 2026
4,285,935	$	3.25	March 16, 2026
1,807,396	$	5.00	February 8, 2027
2,692,604	$	5.00	March 30, 2027
1,200	$	1,680.00	None
20,549,338

XML

Equity Incentive Plans

6 Months Ended

Jun. 30, 2023

Equity Incentive Plans

Equity Incentive Plans

9. Equity Incentive Plans

Stock Award Plans

The Company maintains a 2016 Equity Incentive Plan (the “2016 Plan”), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable over a four-year period following the date of grant. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually beginning January 1, 2017 and through January 1, 2026.

The Company has issued restricted stock awards (“RSAs”) under certain legacy option plans that generally vest two to four years based on service conditions. The RSAs began vesting in May 2019, and no additional awards will be issued under this legacy plan.

Share-based Compensation

The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model (“Black-Scholes”). Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period.

The assumptions used in the Black-Scholes model during the six months ended June 30, 2023 and 2022 are presented below.

	Six months ended
	June 30, 2023	June 30, 2022
Risk-free interest rate	3.54% - 4.20%	2.65% - 3.52%
Expected volatility	90.99% - 91.58%	84.81% - 85.67%
Expected term (in years)	5.50 - 7.00	5.50 - 7.00
Expected dividend yield	0%	0%

The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based on the historical volatility of Armata and peer companies’ common stock. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the SEC Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. For stock options granted to parties other than employees or directors, the Company elects, on a grant-by-grant basis, to use the expected term or the contractual term of the option award. The Company has never declared or paid dividends on its Common Stock and has no plans to do so in the foreseeable future. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.

The tables below summarize the total share-based compensation expense included in the Company’s consolidated statements of operations for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Research and development	$	259,000	$	489,000	$	804,000	$	679,000
General and administrative		2,000		460,000		314,000		763,000
Total share-based compensation	$	261,000	$	949,000	$	1,118,000	$	1,442,000

Stock option transactions during the six months ended June 30, 2023 are presented below:

	Options Outstanding
				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Term	Intrinsic
	Shares	Price		(Years)	Value
Outstanding at December 31, 2022	3,352,803	$	5.32	7.8
Granted	17,500		2.36
Exercised	—		—		$	—
Forfeited/Cancelled	(168,374)		5.63
Outstanding at June 30, 2023	3,201,929	$	5.29	7.3	$	—
Vested and expected to vest at June 30, 2023	3,201,929	$	5.29	6.7	$	—
Exercisable at June 30, 2023	2,142,829	$	5.57	7.3	$	—

Restricted stock award transactions under the Assumed 2016 Plan and restricted stock unit award transactions during the six months ended June 30, 2023 are presented below:

		Weighted Avg
		Grant Date
	Shares	Fair Value
Outstanding at December 31, 2022	129,666	$	27.11
Granted	—		—
Forfeited/Cancelled	(3,699)		39.54
Vested and Issued as Common Stock	(54,901)		29.97
Outstanding at June 30, 2023	71,066	$	24.25

The aggregate intrinsic value of options at June 30, 2023 is based on the Company’s closing stock price on that date of $1.14 per share. As of June 30, 2023, there was $1.7 million of total unrecognized compensation expense related to unvested stock options and RSAs, which the Company expects to recognize over the weighted average remaining period of approximately 1.78 years.

Shares Reserved for Future Issuance

As of June 30, 2023, the Company had reserved shares of its Common Stock for future issuance as follows:

	Shares Reserved
Stock options outstanding	3,201,929
Unvested restricted stock units	71,066
Employee stock purchase plan	9,748
Available for future grants under the 2016 Plan	2,534,180
Warrants outstanding	20,549,338
Total shares reserved	26,366,261

XML

Income Taxes

6 Months Ended

Jun. 30, 2023

Income Taxes

Income Taxes

10. Income Taxes

The Company did not record a provision or benefit for income taxes during the three and six months ended June 30, 2023 and 2022. As of both June 30, 2023 and December 31, 2022, the Company continues to maintain a full valuation allowance against all of its deferred tax assets in light of its history of cumulative losses.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies

Commitments and Contingencies

11. Commitments and Contingencies

Operating Leases

The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced January 1, 2012 and in April 2020, the Company amended the lease (“2020 Lease Amendment”) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, will be approximately $1.9 million, and base rent increases by 3% annually and will be $2.5 million by the end of the amended term. In addition, the Company received a six-month rent abatement in 2020. The Company did not use an allowance for tenant improvements of $0.8 million during 2021, which will offset rent payments as prescribed by the 2020 Lease Amendment starting in 2022. In accordance with authoritative guidance, the Company re-measured the lease liability in April 2020 to be $11.7 million and related right of use asset of $11.0 million as of the Lease Amendment date with an incremental borrowing rate of 12.89%.

Concurrent with the Company’s execution of the 2020 Lease Amendment, an irrevocable letter of credit in the amount of $1.2 million was delivered to the landlord. Starting on February 1, 2022, and each year thereafter, the letter of credit will be reduced by 20% of the then outstanding amount.

On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the “2021 Lease”). The 2021 Lease payment start date is May 1, 2022 and the total lease term is for 16 years and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately $0.25 million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to $7.3 million, and the Company is responsible for construction costs over such allowance. Out of pocket expenses to be incurred by the Company are considered noncash lease payments, and included in the lease liability and right-of-use asset when the amount can be reasonably estimated. As of November 16, 2022, the Company finalized the budget to complete the construction of the 2021 Lease. Accordingly, the Company re-measured the lease liability and related right-of-use asset as of November 30, 2022, using an incremental borrowing rate of 11.8%. The re-measured lease liability of the 2021 Lease as of November 16, 2022 was $37.0 million, and the related right of use asset was $33.8 million. During the three months ended June 30, 2023, the budget was modified and the Company re-measured the lease liability as of April 30, 2023, and increased the lease liability and related right-of-use asset by approximately $1.0 million, using an incremental borrowing rate of 14.27%.

In connection with the 2021 Lease, the Company delivered an irrevocable standby letter of credit in the total amount of $5.0 million to the landlord in 2022.

Legal Proceedings

From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company’s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company’s consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company’s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.

XML

Grants and Awards

6 Months Ended

Jun. 30, 2023

Grants and Awards

Grants and Awards

12. Grants and Awards

MTEC Grant

On June 15, 2020, the Company entered into a Research Project Award agreement (the “MTEC Agreement”) with the Medical Technology Enterprise Consortium (“MTEC”), pursuant to which the Company received a $15.0 million grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. On September 29, 2022, the MTEC Agreement was modified to increase the total award by $1.3 million to $16.3 million and extend the term into the third quarter of 2024. The MTEC funds are to partially fund a Phase 1b/2a, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections. The MTEC Agreement specifies that the grant will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC.

Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received.

The MTEC Agreement is effective through October 30, 2024. The MTEC Agreement may be terminated in whole or in part, 30 calendar days following written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company.

The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue on the statement of operations when related costs are incurred. The Company recognized $1.0 million and $1.8 million in grant revenue from the MTEC Agreement during the three and six months ended June 30, 2023, respectively. The Company recognized $1.9 million and $3.1 million in grant revenue from the MTEC Agreement during the three and six months ended June 30, 2022, respectively. As of June 30, 2023 and December 31, 2022, the Company had $0.2 million and $1.6 million as unbilled awards receivable from MTEC, respectively.

CFF Therapeutics Development Award

On March 13, 2020, the Company entered into an award agreement (the “Award Agreement”) with CFF, pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the “CFF Award”). The CFF Award will be used to fund a portion of the Company’s Phase 1b/2a clinical trial of the Pseudomonas aeruginosa (“P. aeruginosa”) phage candidate, AP-PA02, as a treatment for Pseudomonas airway infections in people with cystic fibrosis (“CF”).

The first payment under the Award Agreement, in the amount of $1.0 million, became due upon signing the Award Agreement and was received in April 2020. The remainder of the CFF Award will be paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2a clinical trial of AP-PA02, as set forth in the Award Agreement.

If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Award Agreement), for a period of 360 days (an “Interruption”) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the CFF Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Award Agreement that covers the Product for use in treating infections in CF patients (the “CF Field”), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.

Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.

The term of the Award Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Award Agreement. Either CFF or the Company may terminate the Award Agreement for cause, which includes the Company’s material failure to achieve certain development milestones. The Company’s payment obligations survive the termination of the Award Agreement.

The Company concluded that the CFF Award is in the scope of ASC 808. Accordingly, as discussed in Note 3, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. No credits were recognized during the three and six months ended June 30, 2023 or 2022. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.

XML

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The condensed consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed

consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2022 included in the Company’s Form 10-K, filed with the SEC on March 16, 2023. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company’s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.

Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.

In-Process Research and Development ("IPR&D")

In-Process Research and Development (“IPR&D”)

IPR&D assets are intangible assets with indefinite lives and are not subject to amortization. The Company’s IPR&D assets represent capitalized incomplete research projects acquired by the Company, which is related to the development of natural phage combinations for the treatment of Staphylococcus aureus infections (“S. aureus”), examples of which comprise AP-SA01 and AP-SA02. Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization.

Goodwill

Goodwill

Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company’s consolidated statements of operations.

Basic and Diluted Net Loss per Share

Basic and Diluted Net Loss per Share

Net earnings or loss per share (“EPS”) is calculated in accordance with the applicable accounting guidance provided in ASC 260, Earnings per Share. The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common shareholders. The two-class method is an earnings allocation

formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.

Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.  Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method.

The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common shareholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method.

Grants and Awards

Grants and Awards

In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a “customer”, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (“ASC 808”). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, Accounting for Government Grants and Disclosure of Government Assistance, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.

Armata also considers the guidance in ASC Topic 730, Research and Development (“ASC 730”), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability. If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.

Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.

Leases

Leases

The Company determines if an arrangement contains a lease at inception. The Company currently only has operating leases. The Company recognizes a right-of-use operating lease asset and associated short and long-term operating lease liability on its condensed consolidated balance sheet for operating leases greater than one year. The right-of-use assets represent the Company’s right to use an underlying asset for the lease term and the lease liabilities represent the Company’s obligation to make lease payments arising from the lease arrangements. Right-of-use operating lease assets and lease liabilities are recognized based on the present value of the future minimum lease payments, including noncash lease payments, the Company will pay over the lease term. The Company determines the lease term at the inception of each lease, which includes renewal options only if the Company concludes that such options are reasonably certain to be exercised.

As the Company’s leases do not provide an interest rate implicit in the lease, the Company uses its incremental borrowing rate, based on the information available on the date of adoption of Topic 842, Leases, as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Company recognizes rent expense for the minimum lease payments on a straight-line basis over the expected term of the leases. The Company recognizes period expenses, such as common area maintenance expenses, in the period such expenses are incurred.

Research and Development Expenses

Research and Development Expenses

Research and development (“R&D”) costs consist primarily of direct and allocated salaries, incentive compensation, share-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.

Reclassifications

Reclassifications

Certain prior year amounts, including tenant improvement receivable and awards receivable, have been reclassified to conform to the current year presentation. Refer to Note 6 Other Receivables table for details.

Recent Accounting Pronouncements Not Yet Adopted

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance became effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company adopted this ASU as of January 1, 2023 which did not have an impact on its consolidated financial statements or related disclosures.

In August 2020, the FASB issued ​ASU 2020-06​, ​Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)​ (“ASU 2020-06”). ​ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company’s consolidated financial statements.

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value of Financial Assets and Liabilities - Derivative Instruments

Changes in Fair Value of Liabilities

The following table presents the Company’s fair value measurements using level 3 inputs during the three and six months ended June 30, 2023.

	Fair Value
Balance at December 31, 2022	$	—
Net issuance of the Convertible Loan		29,226,000
Change in fair value		3,162,000
Balance at March 31, 2023	$	32,388,000
Change in fair value		(6,036,000)
Balance at June 30, 2023	$	26,352,000

XML

Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2023

Net Loss per Share

Computation of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated:

	Three Months Ended		Six Months Ended
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
Basic and diluted net loss per common share calculation:
Net loss attributable to common shareholders - basic	($ 3,547,000)	($ 9,215,000)	($ 18,037,000)	($ 17,989,000)
Change in fair value of convertible debt	6,036,000	—	2,874,000	—
Net loss attributable to common shareholders - diluted	($ 9,583,000)	($ 9,215,000)	($ 20,911,000)	($ 17,989,000)
Weighted average common shares outstanding - basic	36,068,130	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - basic	($ 0.10)	($ 0.26)	($ 0.50)	($ 0.55)
Weighted average common shares outstanding - diluted	56,544,698	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - diluted	($ 0.17)	($ 0.26)	($ 0.50)	($ 0.55)

Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding

The following outstanding securities as of June 30, 2023 and 2022 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:

	June 30, 2023	June 30, 2022
Options	3,201,929	3,380,678
Unvested restricted stock units	30,000	30,000
Restricted stock awards	41,066	99,666
Warrants	20,549,338	20,549,338
Total	23,822,333	24,059,682

XML

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2023

Balance Sheet Details

Property and Equipment

	June 30, 2023		December 31, 2022
Laboratory and manufacturing equipment	$	15,655,000	$	10,007,000
Furniture and fixtures		817,000		817,000
Office and computer equipment		449,000		449,000
Leasehold improvements		3,447,000		3,447,000
Total		20,368,000		14,720,000
Less: accumulated depreciation		(11,561,000)		(11,103,000)
Property and equipment, net	$	8,807,000	$	3,617,000

Schedule of Other receivables

Other receivables as of June 30, 2023 and December 31, 2022 consisted of the following:

	June 30, 2023		December 31, 2022
Tenant improvement receivable	$	7,375,000	$	6,595,000
Awards receivable		1,258,000		1,936,000
	$	8,633,000	$	8,531,000

XML

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2023

Stockholders' Equity

Summary of Warrant Information

On June 30, 2023, outstanding warrants to purchase shares of Common Stock are as follows:

Shares Underlying Outstanding Warrants	Exercise Price		Expiration Date
1,183,491	$	5.60	October 16, 2023
993,139	$	2.87	February 11, 2025
7,717,661	$	2.87	March 27, 2025
1,867,912	$	3.25	January 26, 2026
4,285,935	$	3.25	March 16, 2026
1,807,396	$	5.00	February 8, 2027
2,692,604	$	5.00	March 30, 2027
1,200	$	1,680.00	None
20,549,338

XML

Equity Incentive Plans (Tables)

6 Months Ended

Jun. 30, 2023

Equity Incentive Plans

Assumptions used in the black-Scholes model

The assumptions used in the Black-Scholes model during the six months ended June 30, 2023 and 2022 are presented below.

	Six months ended
	June 30, 2023	June 30, 2022
Risk-free interest rate	3.54% - 4.20%	2.65% - 3.52%
Expected volatility	90.99% - 91.58%	84.81% - 85.67%
Expected term (in years)	5.50 - 7.00	5.50 - 7.00
Expected dividend yield	0%	0%

Allocation of Stock-Based Compensation Expenses

The tables below summarize the total share-based compensation expense included in the Company’s consolidated statements of operations for the periods presented:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Research and development	$	259,000	$	489,000	$	804,000	$	679,000
General and administrative		2,000		460,000		314,000		763,000
Total share-based compensation	$	261,000	$	949,000	$	1,118,000	$	1,442,000

Summary of Stock Option Activity

Stock option transactions during the six months ended June 30, 2023 are presented below:

	Options Outstanding
				Weighted
				Average
		Weighted		Remaining
		Average		Contractual	Aggregate
		Exercise		Term	Intrinsic
	Shares	Price		(Years)	Value
Outstanding at December 31, 2022	3,352,803	$	5.32	7.8
Granted	17,500		2.36
Exercised	—		—		$	—
Forfeited/Cancelled	(168,374)		5.63
Outstanding at June 30, 2023	3,201,929	$	5.29	7.3	$	—
Vested and expected to vest at June 30, 2023	3,201,929	$	5.29	6.7	$	—
Exercisable at June 30, 2023	2,142,829	$	5.57	7.3	$	—

Schedule of restricted stock awards and restricted stock unit activity

Restricted stock award transactions under the Assumed 2016 Plan and restricted stock unit award transactions during the six months ended June 30, 2023 are presented below:

		Weighted Avg
		Grant Date
	Shares	Fair Value
Outstanding at December 31, 2022	129,666	$	27.11
Granted	—		—
Forfeited/Cancelled	(3,699)		39.54
Vested and Issued as Common Stock	(54,901)		29.97
Outstanding at June 30, 2023	71,066	$	24.25

Shares Reserved for Future Issuance

As of June 30, 2023, the Company had reserved shares of its Common Stock for future issuance as follows:

	Shares Reserved
Stock options outstanding	3,201,929
Unvested restricted stock units	71,066
Employee stock purchase plan	9,748
Available for future grants under the 2016 Plan	2,534,180
Warrants outstanding	20,549,338
Total shares reserved	26,366,261

XML

Liquidity (Narrative) (Details)				6 Months Ended
	Jan. 10, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($) shares	Feb. 09, 2022 USD ($) tranche $ / shares shares	Jun. 30, 2023 USD ($) $ / shares	Jul. 10, 2023 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Jun. 30, 2022 USD ($)
Liquidity, management evaluation				The Company has prepared its condensed consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern.
Cash and cash equivalents | $				$ 12,456,000		$ 14,852,000	$ 36,978,000
Common stock, par value (in dollars per share) | $ / shares				$ 0.01		$ 0.01
Innoviva Strategic Opportunities LLC [Member] | Secured term loan
Aggregate amount | $	$ 30,000,000
Interest rate (as a percent)	8.00%
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Discount on share price for conversion	15.00%
Price per share | $ / shares	$ 1.52
Innoviva Strategic Opportunities LLC [Member] | Secured term loan | Minimum [Member]
Discount on share price for conversion	15.00%
Innoviva Strategic Opportunities LLC [Member] | Secured term loan | Subsequent Event [Member]
Aggregate amount | $					$ 25,000,000
Interest rate (as a percent)					14.00%
Securities Purchase Agreement [Member] | Innoviva Strategic Opportunities LLC [Member]
Number of tranches | tranche			2
Shares Issued, Price Per Share | $ / shares			$ 5.00
Stock Issued During Period, Shares, New Issues			9,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			4,500,000
Exercise price of warrants | $ / shares			$ 5.00
Securities Purchase Agreement First Tranche [Member] | Innoviva Strategic Opportunities LLC [Member]
Stock Issued During Period, Shares, New Issues			3,614,792
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,807,396
Proceeds from issuance of common stock and warrants | $			$ 18,100,000
Securities Purchase Agreement Second Tranche [Member] | Innoviva Strategic Opportunities LLC [Member]
Stock Issued During Period, Shares, New Issues		5,385,208
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,692,604
Proceeds from issuance of common stock and warrants | $		$ 26,900,000

XML

Fair Value Measurement (Changes in Fair Value of Liabilities) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2023
Change in fair value	$ 6,036,000		$ 2,874,000
Ending balance	26,352,000		26,352,000
Fair Value, Inputs, Level 3 [Member]
Beginning balance	32,388,000
Net issuance of the Convertible Loan		29,226,000
Change in fair value	(6,036,000)	3,162,000
Ending balance	$ 26,352,000	$ 32,388,000	$ 26,352,000

XML

Net Loss per Share (Computation of basic and diluted net loss per share) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Basic and diluted net loss per common share calculation:
Net loss attributable to common shareholders - basic	$ (3,547,000)	$ (9,215,000)	$ (18,037,000)	$ (17,989,000)
Change in fair value of convertible debt	6,036,000		2,874,000
Net loss attributable to common shareholders - diluted	$ (9,583,000)	$ (9,215,000)	$ (20,911,000)	$ (17,989,000)
Weighted average common shares outstanding - basic	36,068,130	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - basic	$ (0.10)	$ (0.26)	$ (0.50)	$ (0.55)
Weighted average common shares outstanding - diluted	56,544,698	35,999,642	36,056,649	32,517,416
Net loss per share of common stock - diluted	$ (0.17)	$ (0.26)	$ (0.50)	$ (0.55)

XML

Net Loss per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	23,822,333	24,059,682
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	3,201,929	3,380,678
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	30,000	30,000
Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	41,066	99,666
Warrant Liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	20,549,338	20,549,338

XML

Balance Sheet Details (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Details
Depreciation	$ 200,000	$ 200,000	$ 458,000	$ 421,000

XML

Balance Sheet Details (Property and Equipment) (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 20,368,000	$ 14,720,000
Less: accumulated depreciation	(11,561,000)	(11,103,000)
Property and equipment, net	8,807,000	3,617,000
Laboratory and manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	15,655,000	10,007,000
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	449,000	449,000
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	817,000	817,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 3,447,000	$ 3,447,000

XML

Balance Sheet Details (Other receivables) (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Balance Sheet Details
Tenant improvement receivable	$ 7,375,000	$ 6,595,000
Awards receivable	1,258,000	1,936,000
Other receivables	$ 8,633,000	$ 8,531,000

XML

Convertible Debt (Narrative) (Details) - Innoviva Strategic Opportunities LLC [Member] $ / shares in Units, $ in Millions	Jan. 10, 2023 USD ($) $ / shares
Proceeds from qualified financing per agreement benchmark	$ 30
Secured term loan
Aggregate amount	$ 30
Interest rate (as a percent)	8.00%
Price per share | $ / shares	$ 1.52
Discount on share price for conversion	15.00%

XML

Stockholders Equity (Narrative) (Details) $ / shares in Units, $ in Millions			6 Months Ended
	Mar. 31, 2022 USD ($) shares	Feb. 09, 2022 USD ($) tranche $ / shares shares	Jun. 30, 2022 shares	Jun. 30, 2023 shares	Dec. 31, 2022 shares
Class of Stock [Line Items]
Common stock, shares authorized				217,000,000	217,000,000
Common Stock
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)			9,000,000
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)		9,000,000
Shares Issued, Price Per Share | $ / shares		$ 5.00
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,500,000
Exercise price of warrants | $ / shares		$ 5.00
Number of tranches | tranche		2
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement First Tranche [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)		3,614,792
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,807,396
Proceeds from issuance of common stock and warrants | $		$ 18.1
Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement Second Tranche [Member]
Class of Stock [Line Items]
Sale of common stock, net of issuance costs (in shares)	5,385,208
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,692,604
Proceeds from issuance of common stock and warrants | $	$ 26.9

XML

Stockholders' Equity (Summary of Warrants Outstanding) (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	20,549,338
Term of warrant	5 years
Exercise Price $5.60
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	1,183,491
Exercise Price | $ / shares	$ 5.60
Warrant Expiration Date	Oct. 16, 2023
Exercise Price $2.87
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	993,139
Exercise Price | $ / shares	$ 2.87
Warrant Expiration Date	Feb. 11, 2025
Exercise Price $2.87.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	7,717,661
Exercise Price | $ / shares	$ 2.87
Warrant Expiration Date	Mar. 27, 2025
Exercise Price $3.25.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	1,867,912
Exercise Price | $ / shares	$ 3.25
Warrant Expiration Date	Jan. 26, 2026
Exercise Price $3.25
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	4,285,935
Exercise Price | $ / shares	$ 3.25
Warrant Expiration Date	Mar. 16, 2026
Exercise Price $5.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	1,807,396
Exercise Price | $ / shares	$ 5.00
Warrant Expiration Date	Feb. 08, 2027
Exercise Price $5.00.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	2,692,604
Exercise Price | $ / shares	$ 5.00
Warrant Expiration Date	Mar. 30, 2027
Exercise Price 1680.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants	1,200
Exercise Price | $ / shares	$ 1,680.00

XML

Equity Incentive Plans (Narrative) (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Stock Option [Member]
Common stock closing price | $ / shares	$ 1.14
Unrecognized compensation cost related to unvested options | $	$ 1.7
Restricted Stock Awards [Member]
Additional awards | shares	0
Restricted Stock Awards [Member] | Minimum [Member]
Vesting period of share-based compensation award	2 years
Restricted Stock Awards [Member] | Maximum [Member]
Vesting period of share-based compensation award	4 years
Stock Options And Restricted Stock Awards [Member]
Weighted-average remaining period for recognition of compensation costs related to unvested options	1 year 9 months 10 days
Equity Incentive Plan 2016 [Member]
Vesting period of share-based compensation award	4 years
Equity Incentive Plan 2016 [Member] | Maximum [Member]
Expiration period of share-based payment award	10 years

XML

Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details) - Common Stock Options [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Measurement Input, Expected Dividend Rate [Member]
Fair value input, equity securities	0	0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value input, equity securities	3.54	2.65
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair value input, equity securities	90.99	84.81
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair value input, equity securities	5.50	5.50
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value input, equity securities	4.20	3.52
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair value input, equity securities	91.58	85.67
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair value input, equity securities	7.00	7.00

XML

Equity Incentive Plans (Allocation of Share-Based Compensation Expense) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 261,000	$ 949,000	$ 1,118,000	$ 1,442,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	259,000	489,000	804,000	679,000
General and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 2,000	$ 460,000	$ 314,000	$ 763,000

XML

Equity Incentive Plans (Summary of Stock Option Activity) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Equity Incentive Plans
Shares, Balance Beginning	3,352,803
Shares, Granted	17,500
Shares, Forfeited/Cancelled	(168,374)
Shares, Balance Ending	3,201,929	3,352,803
Vested and expected to vest at June 30, 2023	3,201,929
Exercisable at June 30, 2023	2,142,829
Weighted Average Exercise Price, Outstanding Beginning	$ 5.32
Weighted Average Exercise Price, Granted	2.36
Weighted Average Exercise Price, Forfeited/Cancelled	5.63
Weighted Average Exercise Price, Outstanding Ending	5.29	$ 5.32
Weighted Average Exercise Price, Vested and expected to vest at June 30, 2023	5.29
Weighted Average Exercise Price, Exercisable at June 30, 2023	$ 5.57
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years 3 months 18 days	7 years 9 months 18 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at June 30, 2023	6 years 8 months 12 days
Weighted Average Remaining Contractual Term (Years), Exercisable at June 30, 2023	7 years 3 months 18 days

XML

Equity Incentive Plans (Restricted stock award and restricted stock unit award activity) (Details) - Restricted stock unit	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Shares
Outstanding at beginning of period (in shares) | shares	129,666
Forfeited/Cancelled (in shares) | shares	(3,699)
Vested and Issued as Common Stock (in shares) | shares	(54,901)
Outstanding at end of period (in shares) | shares	71,066
Weighted Avg Grant Date Fair Value
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 27.11
Forfeited/Cancelled (in dollars per share) | $ / shares	39.54
Vested and Issued as Common Stock (in dollars per shares) | $ / shares	29.97
Outstanding at end of period (in dollars per share) | $ / shares	$ 24.25

XML

Equity Incentive Plans (Shares Reserved for Future Issuance) (Details) - shares	Jun. 30, 2023	Dec. 31, 2022
Stock options outstanding	3,201,929	3,352,803
Warrants outstanding	20,549,338
Total shares reserved	26,366,261
Unvested Restricted Stock Units [Member]
Unvested restricted stock units	71,066	129,666
Stock Option [Member]
Unvested restricted stock units	9,748
Equity Incentive Plan 2016 [Member]
Available for future grants under the 2016 Plan	2,534,180

XML

Income Taxes (Narrative) (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Taxes
Income tax expense (benefit)	$ 0	$ 0	$ 0	$ 0

XML

Commitments and Contingencies (Narrative) (Details) - USD ($)		1 Months Ended	6 Months Ended
	Apr. 30, 2023	Apr. 30, 2020	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Nov. 30, 2022	Nov. 16, 2022	Oct. 28, 2021
Lease term								16 years
Base annual rent for 2024								$ 250,000
Maximum allowance for tenant improvements								7,300,000
Operating lease expected yearly base rent		$ 1,900,000
Annual increase in rent percentage		3.00%
Base rent at the end of lease term		$ 2,500,000
Period of lease and rental abatement credit		6 months
Lease and rental abatement credit		$ 800,000
Operating Lease, Liability		11,700,000					$ 37,000,000.0
Operating Lease, Right-of-Use Asset		$ 11,000,000.0	$ 43,652,000		$ 43,035,000		$ 33,800,000
Lessee, Operating Lease, Discount Rate		12.89%				11.80%
Standby letter of credit								$ 5,000,000.0
Increase (decrease) operating lease right-of-use and liability			$ (7,474,000)	$ 1,781,000
2021 Lease [Member]
Lessee, Operating Lease, Discount Rate	14.27%
Increase (decrease) operating lease right-of-use and liability	$ 1,000,000.0
Cash [Member]
Standby letter of credit		$ 1,200,000
Annual reduction of standby letter of credit		20.00%

XML

Grants and Awards (Narrative) (Details) - USD ($)				3 Months Ended		6 Months Ended
	Sep. 29, 2022	Jun. 15, 2020	Mar. 13, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Award [Line Items]
Revenue from grants				$ 980,000	$ 1,883,000	$ 1,776,000	$ 3,119,000
Medical Technology Enterprise Consortium [Member]
Award [Line Items]
Revenue from grants	$ 16,300,000	$ 15,000,000.0		1,000,000.0	1,900,000	1,800,000	3,100,000
Increase in expected revenue from grants	$ 1,300,000
Unbilled award receivable				$ 200,000	$ 1,600,000	$ 200,000	$ 1,600,000
Cystic Fibrosis Foundation [Member]
Award [Line Items]
Award receivable			$ 1,000,000.0
Award agreement interruption period			360 days
Maximum [Member] | Cystic Fibrosis Foundation [Member]
Award [Line Items]
Amount of threshold development award			$ 5,000,000.0